Nostrum completes proof-of-concept study for thrombolytic protein

In this proof-of-concept study in a non-human primate thrombolysis model, an appropriate dose of SMRX11 was administered as an intravenous bolus and successfully restored femoral arterial blood flow in cynomolgus monkeys following a stable thrombus formation. The animal model utilized has been previously validated on other, FDA approved thrombolytic products such as tPA.

Nostrum’s Symmetrix subsidiary, based in Singapore, is developing this therapeutic protein drug under Nostrum’s license from the Institute of Microbial Technology, Chandigarh, India, which Nostrum obtained in July 2006.

Yatindra Prashar, co-founder of Symmetrix, said: “We have seen promising results in this primate model. We were clearly able to demonstrate the utility of SMRX11. Further studies will be conducted to show efficacy and safety of the product prior to our planned clinical studies in humans.”